title: [Nephrology].
abstract: Advances in biomedical technology have contributed effectively to the resolution of basic and clinical problems in Nephrology. Most of our insights on glomerular diseases come from animal models. Antibodies against components of the extracellular matrix have been shown to induce glomerular changes in vivo and the non-collagenous NC1 domain of type IV collagen has been demonstrated to contain the Goodpasture antigen. New pathogenetic mechanisms of glomerular injury are suggested by studies on the interaction of antibodies with glomerular cell surface antigens. Gp330, a glycoprotein expressed at the surface of glomerular visceral epithelial cells, has been recognized to be the most relevant antigen of Heymann nephritis. Antibodies able to crosslink gp330 bind to the antigen at the base of foot processes and the resulting immune complexes are shed into the subepithelial space where they form electron dense deposits. The complement membrane attack complex (C5b-9) is likely to be directly responsible for epithelial cell injury and proteinuria in this model. Other cell surface antigens of the glomerular capillary wall, such as dipeptidyl dipeptidase IV, podocalyxin, podoendin, have been characterized. A novel model of glomerular injury comes from the demonstration that a non-complement fixing monoclonal antibody to a surface sialo-glycoprotein (SGP-115/107) binds to glomerular visceral epithelial cells and causes morphological changes which appear epitope-specific and complement and leukocyte-independent. The mechanisms responsible for the progression of renal disease to glomerular sclerosis have been extensively explored in the last years. Among the hemodynamic factors intraglomerular hypertension has been established to play an important part, at least in some models.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: M
authors.initials: M
authors.lastname: Abbate
authors.forename: G
authors.initials: G
authors.lastname: Remuzzi
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D003524:Cyclosporins / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000150:complications / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007111:Immunity, Cellular; D007674:Kidney Diseases / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D009395:Nephritis, Interstitial / Q000276:immunology
chemical_list: D003524:Cyclosporins; D004921:Erythropoietin
vernacular_title: Nefrologia.